ArticleJournal of neuro-oncology2026
Novel cilengitide derivatives suppress migration and invasion of temozolomide-resistant glioblastoma cells via MAPK/Akt pathway inhibition.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundTemozolomide (TMZ) resistance and the invasive nature of glioblastoma (GBM) significantly limit therapeutic outcomes. Cilengitide, an RGD-containing integrin inhibitor, has shown anti-migratory effects, but its potential in TMZ-resistant GBM remains unclear. This study evaluated cilengitide and newly synthesized derivatives for their ability to inhibit migration and invasion in TMZ-resistant GBM cells.
methodsT98G cells were treated with cilengitide and seven derivatives. Cell viability, apoptosis, migration, and invasion were assessed using 2D assays and 3D spheroid models. Gene expression was analyzed by qRT-PCR, and MAPK/Akt signaling was examined by Western blotting. Combination effects with the tyrosine kinase inhibitor dovitinib were evaluated using wound healing and invasion assays.
resultsAmong the derivatives, R-1 and R-7 significantly reduced cell viability and induced PARP-1 cleavage, similar to cilengitide. Both peptides inhibited migration and invasion in a concentration-dependent manner and suppressed MMP2/MMP9 expression. R-1 primarily reduced Akt phosphorylation, whereas cilengitide and R-7 inhibited JNK activation. In 3D spheroids, cilengitide derivatives modestly affected viability but markedly impaired migratory capacity. Co-treatment with dovitinib produced a synergistic inhibition of migration and invasion compared with single-agent treatment.
conclusionCilengitide derivatives R-1 and R-7 effectively suppress migration and invasion of TMZ-resistant GBM cells through inhibition of MAPK/Akt signaling and matrix-degrading enzymes. Their synergistic interaction with dovitinib highlights the potential of peptide-based integrin antagonists as combination therapeutic candidates for overcoming TMZ resistance in GBM.
Indexed as
Identifiers
41903077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.